Ivermectin and Cancer: Dosage and Treatment Claims

I- i- if we start off with, with, uh ... Let's start off with ivermectin.

What, what sort of doses might we be thinking about for what's ...

M- maybe just give some examples of conditions that you've, y- where you've got personal experience.

The starting dose, uh, that I look at with ivermectin is one milligram per kilogram per day.

Quite high. And, and it is a little bit high. Uh, uh, I always say this is about five, about five times the dose that you would use for COVID-19 or, or a parasite infection, for example.

Yeah. Is thi- And- Is, is this with ... What, what level of cancer is this with? Sorry.

This would be with, with, with most cancers, sort of intermediate to high-grade cancers. Now, for low-grade cancers, you could certainly start lower at, at half a, half a milligram per kilogram per day.

And so for a 60-kilogram person, uh, typical starting dose would be about 60 milligrams of ivermectin.

But for low-grade ca- something like, uh, CLL, chronic lymphocytic leukemia, that's been, you know, simmering for many years, or maybe, maybe multiple myeloma, I start lower at, at half a milligram per kilogram.

So that'll be something like 30 milligrams- Right ... of ivermectin a day. Uh, and that's more in the range of a, a, a dose for, uh, a viral infection or a parasitic infection.

Yeah. Uh- And is that six days a week? That's seven days a week.

Seven days a week. Seven. For, for how many weeks?

Uh, well, so I suggest, um, patients try ivermectin, uh, for cancer for three months, and I'll tell you the reasoning behind that.

Uh, and then with a reassessment of some kind, looking at blood work, uh, cancer markers, for example, or looking at follow-up imaging.

Um, the reason why I say three months is because from my experience, I have seen, uh, a response to ivermectin on cancer markers as early as three, four weeks.

So this is, uh, markers like prostate-specific antigen, PSA.

We could see a drop in the PSA. We could see a, a drop in CEA or CA 125, uh, or these other more specialized, uh, markers for breast cancer, for example, like- Th- these are basically chemicals given off by the cancer cells- Exactly. And you can see- ... that allow us to- And you can s- you can see those start to drop.

Now, they are, they're not perfect tests, but they are surrogates for cancer activ- the level of cancer activity or- Mm-hmm ... the level of tu- tumor burden. Uh, how much cancer, how much active cancer is there, uh, that where these cancer cells are producing these markers.

You could see those markers start to drop, and you can actually start to see, uh, the activity of the tumors start to drop on a, on a PET scan, a positron emission tomography scan, uh, in about a month.

But it takes a little bit longer to start seeing tumors physically shrink, uh, lymph nodes shrink, you know, primary tumor shrink.

That takes about two to three months to see that, to start seeing that on imaging like MRI, PET CT, or CT. So you wanna give it a good three months to see if, if you've got, if you have a response. You could, you could, you could monitor it on the blood markers.

Um, within a month or so, you could start seeing if there is a response, and then after two, three months, you could actually start seeing, uh, responses on imaging. And I'll tell you the most dramatic results that I've seen, and I get attacked from both sides. I get attacked from conventional oncology on this, and

I g- I get attacked from the sort of health freedom movement on this.

But the best results I've seen in my patients are patients who are doing a combination of chemotherapy and ivermectin.

Um- ... and then combine it with, uh, either fenbendazole ... and then combine it with, uh, either fenbendazole or albendazole as well.

A- and but when you do the combination treatment- Mm ... there's a certain synergy. Uh- Mm ... and, and that synergy's documented in preclinical research- Mm ... uh, where you get a lot more cancer cell killing with the combination than with any of those agents by themselves.

Well, it's consistent with, with what we were saying before about the sensitization of the malignant cells.